Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Exposure to a pathogen elicits an adaptive immune response aimed to control and eradicate. Interrogating the abundance and specificity of the naive B cell repertoire contributes to understanding how to potentially elicit protective responses. Here, we isolated naive B cells from 8 seronegative human donors targeting the SARS-CoV-2 receptor-binding domain (RBD). Single B cell analysis showed diverse gene usage with no restricted complementarity determining region lengths. We show that recombinant antibodies engage SARS-CoV-2 RBD, circulating variants, and pre-emergent coronaviruses. Representative antibodies signal in a B cell activation assay and can be affinity matured through directed evolution. Structural analysis of a naive antibody in complex with spike shows a conserved mode of recognition shared with infection-induced antibodies. Lastly, both naive and affinity-matured antibodies can neutralize SARS-CoV-2. Understanding the naive repertoire may inform potential responses recognizing variants or emerging coronaviruses enabling the development of pan-coronavirus vaccines aimed at engaging germline responses.
One Sentence Summary
Isolation of antibody germline precursors targeting the receptor binding domain of coronaviruses.
Article activity feed
-
SciScore for 10.1101/2021.02.02.429458: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: All experiments were conducted with MGH Institutional Biosafety Committee approval (MGH protocol
IRB: Additionally, the control convalescent sera used for ELISA was obtained under the approved Partners Institutional Review Board (protocol 2020P000895) for use of patient samples for the development and validation of SARS-CoV-2 diagnostic tests (9).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources ACE-2 cell binding assay: ACE-2 expressing 293T cells were incubated with 200 nM of RBD antigen … SciScore for 10.1101/2021.02.02.429458: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: All experiments were conducted with MGH Institutional Biosafety Committee approval (MGH protocol
IRB: Additionally, the control convalescent sera used for ELISA was obtained under the approved Partners Institutional Review Board (protocol 2020P000895) for use of patient samples for the development and validation of SARS-CoV-2 diagnostic tests (9).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources ACE-2 cell binding assay: ACE-2 expressing 293T cells were incubated with 200 nM of RBD antigen in PBS for 1hr on ice. ACE-2suggested: None293Tsuggested: NoneThe titers of viral supernatants were determined via flow cytometry on 293T-ACE2 cells (72) and via the HIV-1 p24CA antigen capture assay (Leidos Biomedical Research, Inc.). 293T-ACE2suggested: RRID:CVCL_YZ65)Software and Algorithms Sentences Resources (GraphPad Software). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Flow cytometry data was analyzed using FlowJo software version 10.7.1. FlowJosuggested: (FlowJo, RRID:SCR_008520)Data were analyzed using Graphpad Prism. Graphpad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from scite Reference Check: We found no unreliable references.
-
